GlassScriptPhysician profile
Robert W Nguyen
NPI 1144256900
$3,374.30
in general payments reported to CMS, 2019-2025
11 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $518 · 2020: $740 · 2021: $658 · 2022: $374 · 2023: $370 · 2024: $285 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,083.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $1,602.14 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.20 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $424.56 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $266.57 | 2022-2024 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $168.98 | 2019-2023 | Gardasil 9, M-M-R II, Vaxelis |
| Glaxosmithkline, LLC. | $159.69 | 2019-2021 | |
| Abbvie INC. | $111.37 | 2021-2024 | |
| Allergan, INC. | $102.06 | 2019 | |
| Lilly USA, LLC | $58.65 | 2021-2022 | |
| Pfizer INC. | $20.70 | 2023 | |
| Genentech USA, INC. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.